The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:

18 Years and older (Adult, Senior)

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria, including, but not limited to:

Clinical diagnosis of macular atrophy (MA) secondary to Stargardt disease (STGD) in one or both eyes

Adequate clarity of ocular media and adequate pupillary dilation to permit good quality imaging of MA in the study eye

Able and willing to provide written informed consent before undergoing any study-related procedures

Able to reliably administer oral medication by self or with available assistance

Exclusion Criteria, including, but not limited to:

Macular atrophy associated with a condition other than STGD in either eye.

Presence in either eye of an active ocular disease that in the opinion of the Investigator compromises or confounds visual function.

History of any intraocular or ocular surface surgery in either eye within 3 months of screening.

Current or previous participation in an interventional study to treat STGD using gene therapy or stem cell therapy at any time, or participation in an interventional study of a vitamin A derivative ≤3 months prior to screening.

Pre-specified laboratory abnormalities at screening

Presence of other medical or ophthalmic disease, physical examination finding, or clinical laboratory finding that in the opinion of the Investigator may contraindicate the use of an investigational drug and place the subject at risk

Current or history of cancer (except for adequately treated basal cell or squamous cell carcinoma of the skin) within 1 year of screening

Anticipated hospitalization for a medical/surgical procedure(s) that could result in interruption/premature cessation of study treatment or participation.

Electrocardiogram with a clinically significant abnormal finding

Female subjects who are pregnant or lactating

Female subjects of childbearing potential or male subjects who are not surgically sterile who are not willing to practice a medically accepted method of birth control with their sexual partner from screening through 30 days after the final dose of study drug